Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. SWKH
SWKH logo

SWKH Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy SWK Holdings Corp (SWKH) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
16.770
1 Day change
-0.18%
52 Week Range
17.900
Analysis Updated At
2026/03/20
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

SWK Holdings Corp (SWKH) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the company has shown strong financial performance in its latest quarter, there are no significant positive catalysts, trading signals, or news to suggest an immediate buying opportunity. The technical indicators are neutral to slightly bullish, but the lack of momentum and trading trends makes it prudent to hold off on investing right now.

Technical Analysis

The stock shows slightly bullish moving averages (SMA_5 > SMA_20 > SMA_200), and the MACD histogram is positive but contracting. RSI is neutral at 41.572, indicating no clear overbought or oversold conditions. Key support and resistance levels are Pivot: 16.751, R1: 17.114, and S1: 16.388. Overall, technical indicators suggest a neutral to slightly bullish trend, but not a strong buy signal.

Positive Catalysts

  • The company reported strong financial performance in Q3 2025, with revenue up 4.45% YoY, net income up 153.17% YoY, and EPS up 157.14% YoY. Gross margin remains at 100%.

Neutral/Negative Catalysts

  • No recent news, significant trading trends, or congress trading data. Hedge funds and insiders are neutral, and there is no clear momentum in the stock. Additionally, the stock trend indicates a potential short-term decline (-2.87% in the next week).

Financial Performance

In Q3 2025, SWKH showed strong growth with revenue increasing to $10.88M (up 4.45% YoY), net income rising to $8.78M (up 153.17% YoY), and EPS improving to 0.72 (up 157.14% YoY). Gross margin remained steady at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target data is available for SWKH.

Wall Street analysts forecast SWKH stock price to rise
Analyst Rating
0
Wall Street analysts forecast SWKH stock price to rise
Buy
Hold
Sell
0
Current: 16.800
sliders
Low
0
Averages
0
High
0
0
Current: 16.800
sliders
Low
0
Averages
0
High
0
Maxim
Maxim
Buy
downgrade
$21 -> $18
AI Analysis
2025-05-19
Reason
Maxim
Maxim
Price Target
$21 -> $18
AI Analysis
2025-05-19
downgrade
Buy
Reason
Maxim lowered the firm's price target on SWK Holdings to $18 from $21 and keeps a Buy rating on the shares. The tangible book value on the stock is down after the company's sale of its pharma royalty portfolio and the payout of its $4 per share special dividend, the analyst tells investors in a research note.

People Also Watch